As previously disclosed on November 26, 2020, an exclusive distributor agreement covering Calmark’s test for assessment of COVID-19 disease severity has been signed with Prisma. The agreement contains a minimum contract volume of MSEK 4.6.
“We are happy that Prisma now is eager to get started with demonstrating and getting to know the product,” says Magdalena Tharaldsen, Director International Business Development at Calmark. “It feels good to be able to supply such a vital product to Italy, where the situation has been dire for a long time. There is a need there for a reliable measuring instrument with analysis results that can provide critical decision support in the assessment of which patients are in genuine need of intensive care.”
Every care has been taken in the translation of this document. In the event of discrepancies, the Swedish original will supersede the English translation.